

biophta

Disrupt Ophthalmology & change patients' lives.



2026 / 01 / 15



Eye drops
200M people worldwide



Intraocular injections
15M people every year

Lack of compliance: #1 unmet medical need in Ophthalmology ⁽¹⁾

IMPROVING THE EFFICACY OF EYE TREATMENTS



MASS
EYE AND EAR
Sense Life. Experience Life.

Prof. David Friedman, M.D., Ph.D.

Harvard Medical School

*Most patients regularly forget about their
eye drops, favoring disease progression*




*Frequent & unpleasant injections
cause patients to cease treatment*

**IRREVERSIBLE
VISION LOSS**

45% do not adhere to
of patients their treatment ⁽²⁾

BIOPHTA's ophthalmic insert



Easy self administration by patients


STERILE AND PRELOADED BIOPHTA PROPRIETARY APPLICATOR



preloaded insert application

Developing a new standard of care for ocular diseases

BREAKTHROUGH BIOPOLYMERS TECHNOLOGY THAT RELEASES DRUGS ON THE EYE



1 Easy to apply & Comfortable


2 *in-situ* Gelation & Strong adhesion

3 7 days of continuous Drug Delivery




ONE topical insert provides 7-Day controlled dose release

IN-VIVO : ONE-WEEK RABBIT PHARMACOKINETIC TRIAL



Topical treatment for addressing retinal diseases

ENHANCED DRUG PERMEATION THROUGH THE EPITHELIUM




Increased Drug penetration boost the build-up of a Drug concentration gradient :



Greater Drug concentration for treating the back-of-the-eye

BIOPHTA inserts also provide sustained Drug release in retina

IN-VIVO RABBIT PHARMACOKINETIC STUDY



Dexamethasone concentration in retina following one insert application


93%
**LONG-TERM
ACCEPTANCE**

**VERY GOOD
TOLERANCE**

**CONTINUOUS
DELIVERY**

Retina : a disruptive non-invasive therapy for DME


TOPICAL TREATMENT OF DIABETIC MACULAR EDEMA



Diabetic Macular Edema

1.5m diagnosed patients worldwide

→ regular injections of anti-VEGF / Steroids



Total Retina market :

- \$13 Bn globally
- 11% CAGR

Replacing frequent injections by one-week non-invasive ocular insert

The only topical treatment to generate a superior outcome

THE FIRST ONE-WEEK SUSTAINED RELEASE & NON-INVASIVE TREATMENT

TOPICAL



Ocular Insert



New eye drops

Companies

biophta

NOVALIQ
Oculis

Better Eye tissues penetration



Prolonged Duration of Action



INJECTIONS



Long-acting implants



Injection Devices



New biologic Drugs



Long-acting Gel Solutions



1

Topical, non-invasive form

2

One-week prolonged duration of action

3

Increased drug penetration in eye

**Our drug delivery platform
has the ability to be used
in multiple treatments.**

ONGOING DISCUSSIONS WITH
7 OPHTHA. PHARMA COMPANIES.

Disease



Market



BO-001 GLAUCOMA



\$6.9 Bn Global Market

**BO-002 RETINA
DIABETIC MACULAR EDEMA**



\$4.3 Bn Global Market

DRY EYE – all stages



\$5 Bn Global market

ANTIBIOTICS



\$1.5 Bn Global market

ALLERGIC CONJUNCTIVITIS



\$2.5 Bn Global market

POST-SURGICAL TREATMENT



CATARACT SURGERIES =
8.5m cases/year (USA + EU)

BIOPHTA 3-step strategy

longer
term



ASO – topical Gene therapy

- Vectorization of Antisens Oligonucleotides (ASO) for the treatment of retinal inherited diseases

step 2



BO-002 Retina – replacing intraocular injections

- First self-applied treatment allowing one-week of sustained Drug release

step 1




BO-001 Glaucoma – platform validation

- 7-Days continuous treatment enables an accelerated pathway to First-in-Human




-validated fast-track pathway – pre-IND meeting




Financing phased on our R&D program needs

OUR FINANCING WILL BALANCE NON-DILUTIVE AND EQUITY FINANCING



Highly complementary team developing game changing technology



ACADEMIC PARTNERS



UNIVERSIDAD
COMPLUTENSE
MADRID

biophta

CHANGE PATIENTS LIVES

1
**Unique non-
invasive insert**
7 days of continuous
Drug Delivery

2
**A platform
addressing
a \$30 Bn market**

3
2027 Series A
To achieve First
Topical & non-
invasive retina
treatment